Ticker
ABOS

Price
4.08
Stock movement up
+0.20 (5.15%)
Company name
Acumen Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
166.98M
Ent verdi
16.05M
Pris/omsetning
-
Pris/bok
0.85
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-32.00%
3 års avkastning
-
5 års avkastning
-
10 års avkastning
-
Sist oppdatert: 2023-03-22
The following slide deck was published by Acumen Pharmaceuticals, Inc.
27. mars 2023

iO Charts is a Seeking Alpha partner

Acumen Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ABOS) Q4 2022 Earnings Conference Call March 27, 2023 8:00 AM ETCompany ParticipantsAlex Braun - Head IRDaniel O'Connell - President and Chief...
27. mars 2023

iO Charts is a Seeking Alpha partner

UTBYTTE

ABOS betaler ikke utbytte
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
27. mars 2023

iO Charts is a Seeking Alpha partner

Acumen Pharmaceuticals is an early-stage developmental concern focusing on development treatments for Alzheimer's. Click here to read ABOS' investment analysis.
26. desember 2022

iO Charts is a Seeking Alpha partner

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning-
Pris til bok0.85
EV i forhold til salg-
Acumen Pharmaceuticals (ABOS) Q3 2022 Earnings Conference Call Nov 14, 2022 04:30 PM ET
15. november 2022

iO Charts is a Seeking Alpha partner

The following slide deck was published by Acumen Pharmaceuticals, Inc.
14. november 2022

iO Charts is a Seeking Alpha partner

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall40.93M
EPS (TTM)-0.95
FCF per aksje (TTM)-0.69

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)0.00
Bruttofortjeneste (TTM)0.00
Driftsinntekter (TTM)-39.40M
Netto inntekt (TTM)-38.34M
EPS (TTM)-0.95
EPS (1 år fremover)-1.22

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenestemargin (TTM)-

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter157.54M
Netto fordringer121.00K
Samlede omløpsmidler202.56M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler203.26M
Leverandørgjeld2.08M
Kortsiktig/nåværende langsiktig gjeld133.00K
Sum kortsiktig gjeld6.61M
Sum gjeld6.61M
Aksjonærenes egenkapital196.65M
Netto varige driftsmidler196.65M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-27.59M
Kapitalutgifter (TTM)158.00K
Fri kontantstrøm (TTM)-27.75M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-19.50%
Avkastning på eiendeler-18.86%
Avkastning på investert kapital-19.48%
Kontantavkastning på investert kapital-14.10%
Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
14. november 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
24. oktober 2022

iO Charts is a Seeking Alpha partner

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning3.96
Daglig høy4.19
Daglig lav3.90
Daglig volum53K
Tidenes høyeste20.28
1 år analytikerestimat15.83
Beta-
EPS (TTM)-0.95
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon27 Mar 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ABOSS&P500
Nåværende prisfall fra toppnotering-79.88%-17.92%
Høyeste prisfall-84.81%-56.47%
Dato for høyeste fall11 May 20229 Mar 2009
Gj.snittlig fall fra topp-61.23%-11.51%
Gj.snittlig tid til ny topp434 days13 days
Maks tid til ny topp433 days1805 days
Acumen's share price more than doubled because of the Eisai news on lecanemab. Here's why I think ABOS' stock price is unsustainable.
30. september 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
28. september 2022

iO Charts is a Seeking Alpha partner

SELSKAPSOPPLYSNINGER
ABOS (Acumen Pharmaceuticals Inc) company logo
Markedsverdi
166.98M
Markedsverdi kategori
Small-cap
Beskrivelse
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Ansatte
14
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
USA
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
Acumen Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ABOS) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ETCompany ParticipantsJohn Woolford - Investor Relations, WestwickeDaniel...
16. august 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
15. august 2022

iO Charts is a Seeking Alpha partner

FORSTÅ VIRKSOMHETEN
Loading...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week
30. juli 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
30. juni 2022

iO Charts is a Seeking Alpha partner

NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2022 Earnings Call Transcript March 27, 2023 Operator: Thank you for standing by. Welcome to Acumen Pharmaceuticals Full Year 2022 Conference Call and Web...
29. mars 2023
Data describe induced pluripotent stem cell (iPSC)-derived excitatory neurons as a human model for assessing selectivity of drug binding to soluble amyloid beta oligomers in Alzheimer’s diseaseResults...
28. mars 2023
INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, completed enrollment in February 2023 Topline data expected in the third quarter of 2023 Cash, cash equival...
27. mars 2023
CHARLOTTESVILLE, Va. and CARMEL, Ind., March 22, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that ta...
22. mars 2023
CHARLOTTESVILLE, Va. and CARMEL, Ind., March 20, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical developing a novel therapeutic that targets to...
20. mars 2023
CHARLOTTESVILLE, Va. and CARMEL, Ind., March 08, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that ta...
8. mars 2023
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
15. februar 2023
Topline results including safety and proof-of-mechanism data expected in third quarter of 2023CHARLOTTESVILLE, Va. and CARMEL, Ind., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NAS...
13. februar 2023
Here is how Novo Nordisk (NVO) and Acumen Pharmaceuticals, Inc. (ABOS) have performed compared to their sector so far this year.
6. januar 2023
CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company focused on ...
4. januar 2023
Neste side
Acumen Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ABOS) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ETCompany ParticipantsJohn Woolford - IR, WestwickeDaniel O'Connell - President &...
17. mai 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Acumen Pharmaceuticals, Inc. (ABOS) stock at Seeking Alpha.
16. mai 2022

iO Charts is a Seeking Alpha partner